Given these findings, we were led to hypothesize that the combined therapy of LTX-315 with CTLA-4 inhibitors may lead to an optimal synergistic anti-tumor effect on residual tumors after RFA of malignant solid tumors, and may significantly reduce the tumor post-RFA recurrence rate of malignant solid tumors. Here, CTLA4 is linked to neoplasm.